- GelMEDIX has entered a partnership with Catalent to support the development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases.
- Catalent will provide GMP-compliant induced pluripotent stem cells (iPSCs) and contract manufacturing capabilities to support development through clinical stages.
GelMEDIX has announced a global partnership with Catalent to support the development and clinical manufacturing of induced pluripotent stem cell (iPSC)-derived therapies for ocular and retinal diseases. The collaboration will enable GelMEDIX to access Catalent’s GMP-compliant iPSC lines and manufacturing capabilities.
Under the agreement, Catalent will provide iPSC development services and cell therapy manufacturing expertise to support GelMEDIX’s programs. Catalent will also supply proprietary, off-the-shelf GMP iPSC lines and support process development, analytical development, scale-up, and GMP manufacturing as the therapies progress through clinical stages.
The partnership focuses on therapies designed to restore vision in patients with ocular and retinal conditions. GelMEDIX is developing regenerative treatments based on iPSC-derived cells, which will move toward clinical evaluation with Catalent’s support.
“Catalent is proud to work with GelMEDIX to support this important clinical program of next-generation therapies for ocular and retinal diseases.”
David McErlane, Biologics Group President at Catalent
Through the collaboration, Catalent will provide contract manufacturing services and development expertise across early development and clinical stages. The companies stated that establishing the partnership early is intended to accelerate GelMEDIX’s progress toward clinical trials for its vision restoration programs.
